The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Potential Efficacy of a Novel HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Histone deacetylases (HDACs) are a family of enzymes that reduce gene expression and can regulate protein clearance. Inhibitors of HDACs have been reported to be efficacious in... -
Therapeutics Development Initiative, 2009Development of Anti-toll-like Receptor (TLR)-2 Monoclonal Antibody as a Therapeutic Agent in Parkinson's Disease
Objective/Rationale:
Parkinson’s is associated with an inflammatory response, which in the brain is mainly mediated by cells called microglia. Inflammation is normally beneficial helping us fight... -
Therapeutics Development Initiative, 2009Design of Neuroprotective Drugs to Reduce Oxidative Damage and Alpha-synuclein Toxicity in Parkinson's Disease
Objective/Rationale:
Exposure to chemical toxins that stimulate the production of reactive oxygen and nitrogen species (RONS) causes neuronal degeneration and can lead to Parkinson’s disease (PD)... -
Therapeutics Development Initiative, 2009Developing Autophagy Enhancers as Disease-modifying Therapeutics for Parkinson's Disease
Objective/Rationale:
We seek to develop small molecule drugs that promote the cellular process of autophagy as disease-modifying therapy for Parkinson's disease (PD). Autophagy is a highly conserved... -
Therapeutics Development Initiative, 2009Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinson's Disease
Objective/Rationale:
We have identified a small molecule, designated J3, which shows promising neuroprotection in an acute animal model of Parkinson’s disease (PD). To reach our ultimate goal of... -
Biomarkers, 2009Analysis of the Enteric Nervous System Using Routine Colonic Biopsies: A Biomarker of Neurodegeneration in Parkinson's Disease
Objective/Rationale:
The “core” of the neuronal lesions of Parkinson’s disease (PD) is the progressive degeneration of dopamine neurons in the central nervous system (CNS). It is now well established...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.